| HOME >> BIOLOGY >> TECHNOLOGY |
The Company has operations in Vienna, Virginia and Baltimore, Maryland.
CEL-SCI's other products, which are currently in pre-clinical stage, have
shown protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense.
CEL-SCI CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Three Months Ended
June 30,
2008 2007
REVENUE:
Grant revenue $ 3,535 $ -
Rent income - 5,734
Other income - 715
Total Revenue 3,535 6,449
EXPENSES:
Research and development, excluding
depreciation of $7,246 and $21,086
included below 975,183 632,868
Depreciation and amortization 27,743 45,089
General and administrative 1,177,288 3,104,755
Total Expenses 2,180,214 3,782,712
LOSS FROM OPERATIONS (2,176,679) (3,776,263)
GAIN (LOSS) ON DERIVATIVE INSTRUMENTS 206,106 (1,090,471)
INTEREST INCOME 94,333 190,112
INTEREST EXPENSE (113,038) (878,354)
NET LOSS BEFORE INCOME TAXES (1,989,278) (5,554,976)
INCOME TAX PROVISION - -
NET LOSS (1
'/>"/>
| SOURCE CEL-SCI CORPORATION Copyright©2008 PR Newswire. All rights reserved |